PJP - ETF AI Analysis
Top Page
Invesco Dynamic Pharmaceuticals ETF (PJP)
Rating:69Neutral
Price Target:―
Positive Factors
Strong Recent Performance
The ETF has delivered strong gains so far this year and over the past few months, showing solid recent momentum.
Leading Pharmaceutical Holdings
Many of the top positions, including several large, well-known drug companies, have shown strong or steady performance, helping support the fund’s returns.
Focused Exposure to U.S. Health Care
The fund’s heavy focus on U.S. health care companies gives investors targeted exposure to a key defensive sector that can be more resilient in uncertain markets.
Negative Factors
High Sector Concentration
Almost all assets are in the health care sector, so a downturn in pharmaceuticals could hurt the fund more than a broadly diversified ETF.
Limited Geographic Diversification
With nearly all holdings in U.S. companies, the fund offers little exposure to international markets, reducing global diversification.
Above-Average Expense Ratio
The fund’s expense ratio is relatively high for an ETF, which means more of the returns are used to cover fees instead of going to investors.
PJP vs. SPDR S&P 500 ETF (SPY)
AUM573.54M
RegionNorth America
Expense Ratio0.58%
Beta0.53
IssuerInvesco
Inception DateJun 23, 2005
Dividend Yield0.9%
Asset ClassEquity
Index TrackedDynamic Pharmaceutical Intellidex Index (AMEX)
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume33,891
30 Day Avg. Volume42,734
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
166.12Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering28
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
PJP Summary
The Invesco Dynamic Pharmaceuticals ETF (PJP) is a fund that focuses on U.S. drug companies and follows the Dynamic Pharmaceutical Intellidex Index. It holds well-known names like Johnson & Johnson and Pfizer, along with other major pharmaceutical makers. Investors might consider PJP if they want targeted exposure to the health care and drug industry, which can benefit from an aging population and ongoing demand for new medicines. However, this ETF is heavily concentrated in pharmaceutical stocks, so its price can swing with changes in drug approvals, regulation, and overall health care sentiment.
How much will it cost me?The Invesco Dynamic Pharmaceuticals ETF (PJP) has an expense ratio of 0.57%, meaning you’ll pay $5.70 per year for every $1,000 invested. This cost is higher than average because it’s actively managed, focusing on selecting pharmaceutical stocks based on various strategic factors to optimize performance.
What would affect this ETF?The Invesco Dynamic Pharmaceuticals ETF (PJP) could benefit from advancements in drug discovery, regulatory approvals, and the growing demand for pharmaceuticals driven by an aging population. However, it may face challenges from stricter regulations, patent expirations, or pricing pressures in the U.S. market, where it is heavily focused. The performance of its top holdings, such as AbbVie and Eli Lilly, will also play a significant role in shaping its future returns.
PJP Top 10 Holdings
PJP is a pure play on U.S. pharmaceuticals, and its story right now is about big, steady drugmakers balanced by a few high-octane names. Merck and Johnson & Johnson are doing much of the heavy lifting, with rising share prices that give the fund a solid backbone. Gilead, Pfizer, and AbbVie are also contributing, though their momentum is more steady than spectacular. On the flip side, Abbott has been lagging and acting like a small anchor. Smaller players like Amneal and Ligand add punch, but also raise the fund’s risk profile.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Gilead Sciences | 5.58% | $31.88M | $187.15B | 35.15% | 78 Outperform | |
| Pfizer | 5.48% | $31.32M | $163.41B | 20.42% | 74 Outperform | |
| AbbVie | 5.46% | $31.22M | $467.12B | 19.32% | 66 Neutral | |
| Johnson & Johnson | 5.43% | $31.02M | $653.61B | 49.74% | 78 Outperform | |
| Eli Lilly & Co | 5.24% | $29.92M | $1.11T | 63.08% | 72 Outperform | |
| Merck & Company | 5.18% | $29.61M | $367.07B | 89.22% | 80 Outperform | |
| Amgen | 5.15% | $29.39M | $224.15B | 52.62% | 77 Outperform | |
| Abbott Laboratories | 4.74% | $27.05M | $175.27B | -24.14% | 73 Outperform | |
| Amneal Pharmaceuticals | 3.56% | $20.32M | $6.31B | 107.70% | 58 Neutral | |
| Ligand Pharma | 3.47% | $19.80M | $6.01B | 81.42% | 60 Neutral |
PJP Technical Analysis
Neutral
―
Price Trends
125.43
Negative
118.99
Positive
111.91
Positive
Market Momentum
-0.03
Positive
41.60
Neutral
41.29
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For PJP, the sentiment is Neutral. The current price of undefined is equal to the 20-day moving average (MA) of 126.03, equal to the 50-day MA of 125.43, and equal to the 200-day MA of 111.91, indicating a neutral trend. The MACD of -0.03 indicates Positive momentum. The RSI at 41.60 is Neutral, neither overbought nor oversold. The STOCH value of 41.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for PJP.
PJP Peer Comparison
Comparison Results
Performance Comparison
PJP
Invesco Dynamic Pharmaceuticals ETF
123.31
29.30
31.17%
RSPH
Invesco S&P 500 Equal Weight Health Care ETF
―
―
―
XPH
SPDR S&P Pharmaceuticals ETF
―
―
―
PBE
Invesco Dynamic Biotechnology & Genome ETF
―
―
―
PINK
Simplify Health Care ETF
―
―
―
PTH
Invesco DWA Healthcare Momentum ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents